Remove keyword executives
article thumbnail

Grand Rounds January 26, 2024: Advancing the Safe, Effective and Equitable Use of AI in Healthcare (Mark Sendak, MD, MPP; Suresh Balu, MD, MBA)

Rethinking Clinical Trials

The first key decision point is procurement, which begins with identifying a problem and ends with allocation of resources to either build or buy an AI product or solution.

article thumbnail

Grand Rounds February 2, 2024: Strategies for Improving Public Understanding of FDA and the Products It Regulates…Why Should We Care, and What Might We Do? (Susan C. Winckler, RPh, Esq)

Rethinking Clinical Trials

Winckler, RPh, Esq Chief Executive Officer Reagan-Udall Foundation for the FDA Slides Keywords U.S.             Speaker Susan C. Food and Drug Administration, FDA, Misinformation, Communication, Health Information Key Points U.S.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Grand Rounds February 9, 2024: Pragmatic Recruitment of Underrepresented Groups – Experience From the Diuretic Comparison Project (Cynthia Hau, MPH)

Rethinking Clinical Trials

Key elements for successful implementation and execution were having a flexible EHR with systemwide collaboration, a supporting community and excellent study coordination, and aligned incentives. DCP learned that leveraging health systems for large-scale clinical trials is feasible.

article thumbnail

Grand Rounds January 20, 2023: Collaborative Pragmatic Trials in Action: EVOLVE-MI (Mikhail Kosiborod, MD)

Rethinking Clinical Trials

This is a collaborative study with Academic-Industry Partnership with oversight by an Academic Executive Committee. The primary endpoint is a composite of total events including first and recurrent MI, ischemic stroke, any arterial revascularization, and death from any cause.

Trials 130
article thumbnail

Grand Rounds October 20, 2023: A National Initiative to Eliminate Hepatitis C in the United States – Why This Matters to Clinical Trialists (Rachael L. Fleurence, PhD, MSc; Joshua M. Sharfstein, MD)

Rethinking Clinical Trials

PCORnet has been an important resource by executing a query to identify the volume of HCV tests conducted by participating health systems and the number of co-infections with Hepatitis B virus. with the rate of reported acute Hepatitis C cases increasing 400% during 2010-2020. A manuscript is under development.

article thumbnail

Grand Rounds February 23, 2024: Virtual Vigilance: Monitoring of Decentralized Clinical Trials (Adrian Hernandez, MD; Christopher J. Lindsell, PhD)

Rethinking Clinical Trials

            Speakers Adrian Hernandez, MD Executive Director, Duke Clinical Research Institute Vice Dean, Duke University School of Medicine Christopher J.

article thumbnail

Grand Rounds August 4, 2023: AI & ML: Want to Play a Game? (Eric Perakslis, PhD)

Rethinking Clinical Trials

However, gamification could have serious negative effects, and the benefits of these games in health care would relate to how well or how poorly they’re gamified, based on data, execution, and use cases. Serious games pique the interest of people and can increase their likelihood of continuing a behavior.